The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.

Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.

Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.

Latest from The University of Texas MD Anderson Cancer Center


Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 01, 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors

July 21, 2022

Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL

July 21, 2022

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL

June 21, 2022

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Guadecitabine Fails to Improve OS Over Physician’s Choice of Treatment in MDS and CMML

June 21, 2022

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape

June 15, 2022

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Quizartinib Triplet Shows Activity in Heavily Pretreated, FLT3-ITD–Mutated AML

June 11, 2022

The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia who were previously exposed to a FLT3 inhibitor.

Momelotinib Shows Superiority Over Danazol in Symptomatic and Anemic Myelofibrosis

June 11, 2022

Momelotinib demonstrated significant improvements in symptoms, spleen size, and anemia measures compared with danazol in patients with symptomatic and anemic myelofibrosis who previously received treatment with a JAK inhibitor.

Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors

June 07, 2022

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

x